AKT1 and epilepsy: Notably, AKT1, INS, and IL-6 emerged as central nodes, which were functionally associated with lipid metabolic and inflammation processes, particularly glycerophospholipid metabolism, suggesting their potential as key therapeutic targets of XYC for epilepsy treatment.